An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
about
Idiotype vaccination for Non-Hodgkin lymphomaRituximab for thyroid-associated ophthalmopathyRituximab for thyroid-associated ophthalmopathyIdiotype vaccination for Non-Hodgkin lymphomaChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaAn update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaInterleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma modelsStructural basis for recognition of CD20 by therapeutic antibody RituximabParallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practiceRituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.Treatment with rituximab in benign and malignant hematologic disorders in children.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark.Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathyTargeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with RituximabImmunopathogenesis of thyroid eye disease: emerging paradigmsPotent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodiesEfficacy of rituximab in gastric diffuse large B cell lymphoma patientsLong-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004.Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.Rituximab in the treatment of high responding inhibitors in severe haemophilia A.Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.Nanotechnology in dermatology.Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy.Targeting B cells for the treatment of rheumatoid arthritisDNA fusion gene vaccines against cancer: from the laboratory to the clinic.Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma.Continuing challenges in childhood non-Hodgkin's lymphoma.Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization
P2860
Q24186272-863D3E57-7DD7-48AB-B288-1E641D0DC0EFQ24202845-BCB33D21-8C09-44EE-BB00-87F6E2DFF5FCQ24235160-E474DB03-00CD-4792-A42D-F699065A18A6Q24235281-098084F5-E2E8-484C-B3A8-B7543A37A4DDQ24243100-F990C0DE-A6CB-4731-93F5-61F336F9A8D4Q26748601-F28C6E67-F9D7-492E-B439-069A9BCE76BDQ27312250-2EEF0608-9AB7-46F7-AFFD-1C44E5F71ECCQ27644280-AC5D838D-1E19-4711-A19C-491D6D43E9BEQ31164228-569A13FA-E18A-49E2-8BFC-5E0E748955B6Q33359900-84058FE9-2D38-43BE-8391-CEFF354B2665Q33366172-62A77333-73C1-4CBB-B8F3-D692515DAA12Q33367239-785FEAC1-3698-4028-83EE-9AF42F80492BQ33367691-186F836F-AF9F-4C71-873A-D748044A7978Q33374660-2810EAAA-7D30-4A50-B429-C0D93C40B0AAQ33377727-BAFD4700-7651-4210-A0CF-6B7F7AC69289Q33391381-704BBBD2-87A8-4417-99DF-C6779C1EA29AQ33409112-8B87339C-2B53-43E6-A56D-518573B30D39Q33624477-A999F4F9-4B65-491F-BB68-A9A80EF7BAB6Q33741009-6F3C3B1D-9E09-4385-8393-3D7DD43CC7E3Q33789467-ECAE48E7-D841-4D3C-9276-FA675FC1C22AQ33877190-FB567E89-895B-477A-841C-8170B2A57788Q33879457-C9E92052-054D-4646-BF05-169719DAE009Q34056575-B428AFED-216B-4953-982C-3EDBEDD650D2Q34548422-C94F0208-5EAB-49AD-8039-C3A4883AAFC6Q34651588-E0A9593F-22BC-4DC4-93D6-0F16B93AC5F4Q35104686-D9ED5FFA-3E0B-4EBE-9183-327419D508CCQ35120307-98DB4AE4-BDD3-4FAF-8504-1CF9BF109291Q35531665-F19B9455-2F3F-4188-8D4B-3465763F8951Q35678195-4CF6AF1F-1B76-47E5-87C6-0077C34AAC91Q35794365-35A42C91-64D0-4429-BCD5-ABDEE8D79D0CQ35826392-2B7584F6-4AE3-45F3-A6B3-57D96A549BCDQ35848730-02A0C40A-4DCA-47BF-9174-3D747935A4E0Q36194606-282CF400-FC31-429A-893A-335C0822A936Q36228057-F6128DA7-5A05-4B8F-8DB0-EE8AEE49F99DQ36407407-561F3DC1-FC88-4F5D-A063-8F79AD1FC5BCQ36673736-149DB93B-072B-4A29-B551-00AA1F685455Q36792745-E0E5241D-E2F0-42F4-9508-D14459115DE7Q36807184-6E3F2ED3-10C4-4BEB-995D-FABD8FD146EEQ36897408-0A0A2D54-F883-40C1-9B2C-D3A663ABDEF0Q37012630-05CBE197-2846-42A2-BD7E-3C7C5C73D118
P2860
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@ast
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@en
type
label
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@ast
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@en
prefLabel
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@ast
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@en
P2093
P356
P1433
P1476
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
@en
P2093
P304
P356
10.1093/ANNONC/MDG175
P577
2003-04-01T00:00:00Z